Translational Medicine

Translational Medicine
Open Access

ISSN: 2161-1025

+44 1223 790975

Masafumi Taniwaki

  • Review Article
    Principles and Current Topics Concerning Management of Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia
    Author(s): Junya Kuroda and Masafumi TaniwakiJunya Kuroda and Masafumi Taniwaki

    Chronic myeloid leukemia (CML) is a chronic myeloproliferative disorder with leukemic cells featuring the Philadelphia (Ph1) chromosome comprising the reciprocal chromosomal translocation t(9;22)(q34;q22) and the resultant constitutive active Bcr-Abl tyrosine kinase (TK). The introduction of disease-specific molecular targeted agents, that is, TK inhibitors (TKIs) for Bcr-Abl TK, such as the first-in-class TKI imatinib mesylate (IM) or the secondgeneration TKIs (SGIs) nilotinib and dasatinib, has dramatically improved the long-term treatment outcome for CML in this century. In addition, several new SGIs, such as bosutinib or bafetinib, are under development, while ponatinib, which is active against CML refractory for all preceding TKIs, for example, CML with T315I Abl kinase domain mutation, is currently being evaluated in clinical trials. Because those TKIs have different sensitivity.. View More»
    DOI: 10.4172/2161-1025.S2-001

    Abstract PDF

Relevant Topics